Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

Erratum to: Int J Clin Oncol DOI 10.1007/s10147-016-1039-0

In the original publication of the article, Table 4 was published incorrectly. The corrected Table 4 is published with this erratum.

Table 4.

Treatment-related adverse events, all grades (≥30 %) and grade ≥3

	All grades (≥30 %)	Grade ≥3
Rash	85 (82.5)	15 (14.6)
Diarrhea	82 (79.6)	1 (1.0)
Dry skin	82 (79.6)	5 (4.9)
Paronychia	69 (67.0)	1 (1.0)
Stomatitis	65 (63.1)	1 (1.0)
Pruritus	67 (65.0)	3 (2.9)
Decreased appetite	35 (34.0)	2 (1.9)
ALT increased	33 (32.0)	9 (8.7)

ALT alanine aminotransferase